Q2 2026 saw 30% revenue growth, strong MRD and clinical testing performance, and a raised FY 2026 MRD revenue outlook. Strategic separation of MRD and IM businesses and robust cash reserves position the company for continued growth and operational focus.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.